Liverpool Drug Interactions: January update
17 January 2024. Related: PK and drug interactions.
PK and drug interactions
FDA warns Amazon over supplements containing Viagra: hundreds of cases reported over ten years
2 January 2024. Related: PK and drug interactions, Other news.
Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research
1 December 2023. Related: PK and drug interactions, HIV prevention and transmission.
CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz
10 March 2023. Related: Conference reports, PK and drug interactions.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
Early data on injecting CAB/RPV-LA into thigh muscle
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
14 October 2020. Related: Conference reports, PK and drug interactions.
FTC exposure higher in young transgender men than cisgender controls
14 October 2020. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough
14 October 2020. Related: Conference reports, Paediatric care, PK and drug interactions, HIV prevention and transmission.
Drug-drug interactions and COVID-19
27 March 2020. Related: PK and drug interactions, COVID-19: other news, COVID-19: on the web, COVID-19.
Updates to Liverpool University drug interactions website
7 January 2020. Related: PK and drug interactions.
Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
18 October 2019. Related: Conference reports, PK and drug interactions.
Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine
19 June 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants
19 June 2019. Related: Conference reports, Women's health, PK and drug interactions.
Infant dolutegravir exposure through placental and breastmilk transfer
19 June 2019. Related: Conference reports, Pregnancy, PK and drug interactions.
Double-dose levonorgestrel implant does not overcome interaction with efavirenz
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Efavirenz and rifampicin together reduce levels of injectable contraception
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Dolutegravir can be given with 3HP to prevent TB without dose adjustment
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Selected webcasts at CROI 2019
12 March 2019. Related: Conference reports, PK and drug interactions.
No significant decrease in raltegravir free fraction during pregnancy
12 December 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Updates from Liverpool University drug interactions website
12 December 2018. Related: PK and drug interactions.
bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges
13 November 2018. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy
24 August 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates
24 August 2018. Related: Antiretrovirals, PK and drug interactions.
Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen
3 August 2018. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole
29 June 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin
29 June 2018. Related: Conference reports, PK and drug interactions.
Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort
29 June 2018. Related: Conference reports, PK and drug interactions, Side effects.
Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily
8 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Vaginal ring reduces efavirenz but not atazanavir exposures
8 June 2018. Related: Conference reports, PK and drug interactions.
Efavirenz might decrease effectiveness of the vaginal contraceptive ring
16 April 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Twice-daily bictegravir does not overcome drug interaction with rifampicin
16 April 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine
23 February 2018. Related: PK and drug interactions.
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
28 November 2017. Related: Conference reports, PK and drug interactions, TB coinfection.
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
28 November 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Dolutegravir pharmacokinetics in pregnancy
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods
26 June 2017. Related: Antiretrovirals, PK and drug interactions.
Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
New HIV diagnoses in children in UK and Ireland continue to decline
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions, Diagnostics.
World Health Organisation paediatric dosing tool
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions.
Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity
24 April 2017. Related: Conference reports, PK and drug interactions.
Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
27 February 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
29 November 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Nevirapine dosing for treatment of neonates
1 June 2016. Related: Conference reports, Paediatric care, PK and drug interactions.
Pharmacokinetics of old and new TB drugs for children
1 February 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression
1 December 2015. Related: Conference reports, Paediatric care, PK and drug interactions.
Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB
1 December 2015. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, PK and drug interactions.
Pharmacokinetics of four antiretrovirals in pregnancy: data from the PANNA network
1 October 2015. Related: Conference reports, Pregnancy, PK and drug interactions.
Dolutegravir placental transfer moderate in ex vivo model
1 October 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Paediatric dosing of DRV/r
1 October 2015. Related: Conference reports, Paediatric care, PK and drug interactions.
Elvitegravir in children and adolescents
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Pharmacokinetics in pregnancy: darunavir/r and etravirine
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.